In our previous work, based on the phenotype of glomerulosclerosis in patients with both Epstein's or Fetchner's syndrome and the association of risk polymorphisms in MYH9 with idiopathic and HIV-related glomerulosclerosis, we hypothesized that a predominant site of action should be the podocyte. This evidence concerns the gene MYH9 and glomerulosclerosis.